Biosafety

Sitero Celebrates National Biosafety Month With the Launch of Biosafety Consulting Services

Retrieved on: 
Tuesday, October 4, 2022
VP, GLOBE, Responsibility, National Bio and Agro-Defense Facility, Howard Brody, Technology, Biomedical sciences, Industry, Research, Compliance, Biocontainment, Biomedical Research, IBC, Select agent, USDA, Post, Safety, Program, Efficiency, ABSA, SME, University, Gaps, Ethics, Company, NBAF, Sales, Medicine, Biosafety, Biorisk, Clinical

Sitero provides a full suite of offerings to customers, ranging from full-spectrum biosafety programs to bespoke services that supplement customers' in-house capabilities and allow them to focus on their highest priority.

Key Points: 
  • Sitero provides a full suite of offerings to customers, ranging from full-spectrum biosafety programs to bespoke services that supplement customers' in-house capabilities and allow them to focus on their highest priority.
  • While Sitero offers services such as training, program reviews and compliance audits, they have the biosafety expertise and technology-enabled solutions to build a flexible offering to meet any client's needs.
  • "We are excited to be celebrating Biosafety month with the launch of Sitero's Biosafety Consulting services," said, Dr. Sarah Ziegler, VP of Biosafety at Sitero.
  • Dr. Ziegler is responsible for leading the Biosafety and IBC services at Sitero.

Governor McKee Announces Major Life Sciences Development Project to Move Forward in the I-195 Innovation and Design District

Retrieved on: 
Tuesday, October 4, 2022
Research, Professional Services, Start-Up, Other Construction & Property, State, Local, Commercial Building & Real Estate, Small Business, Construction & Property, Science, Urban Planning, Other Science, Public Policy, Government, School, Brown University, Science, Epidemiology, Ownership, Legal & General, Letter, Biosafety, Research, Industry, Commerce, Public health, Economic development, General officer, Alpert Medical School, Molecular medicine, Ancora, Infection, Education, Rhode Island Department of Health, Medicine, Partnership, Jewellery, Design District, RI, CDC, SunLight General Capital, RFP, GRE, Administration, Organization, Technology, Human services, Centre for Molecular Medicine and Therapeutics, Macau University of Science and Technology, Pharmaceutical industry, Health, Laboratory

Governor Dan McKee today announced that a major life sciences development project is moving forward in the states Innovation and Design District on the former I-195 land.

Key Points: 
  • Governor Dan McKee today announced that a major life sciences development project is moving forward in the states Innovation and Design District on the former I-195 land.
  • Rhode Island has momentum and this project is crucial to ensuring the momentum continues in the areas of public health and our economy, said Governor Dan McKee.
  • Were grateful for all the partners who came together to ensure Rhode Island maximizes this significant economic development opportunity while advancing the states important public health goals.
  • The public design review process will begin at the I-195 Redevelopment District Commission meeting on October 19 where Ancora L&G will present their design.

Gov. Hochul Tours Renovated Feinstein Institutes Bioelectronic Medicine Lab, Announces First $10 Million Award

Retrieved on: 
Tuesday, September 27, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Managed Care, Institute, Northwell Health, Health, Molecular medicine, Feinstein Institute for Medical Research, COVID-19, Movement, Feinstein, Autoimmunity, MD, Virus, Credit, Publication, LinkedIn, Lupus, Obesity, Empire State Development Corporation, Intellectual property, Industry, Suffolk Construction Company, Assembly, New Yorkers, Diabetes, Â, Mental health, Commissioner, Genetics, Cancer, CEO, State, Technology, Medical research, Science, Biosafety, Empire, ESD, Research, Biotechnology, Medicine, Multimedia, Sensation, Infection, Pharmaceutical industry, Hospital, New

Hochul also announced a new $10 million ESD grant awarded to the Feinstein Institutes for a second phase of lab renovations.

Key Points: 
  • Hochul also announced a new $10 million ESD grant awarded to the Feinstein Institutes for a second phase of lab renovations.
  • View the full release here: https://www.businesswire.com/news/home/20220927006119/en/
    Michael Dowling (left) with New York State Governor Kathy Hochul (center) as she tours Feinstein Institutes upgraded labs alongside Dr. Kevin Tracey (right).
  • (Credit: Feinstein Institutes)
    Michael Dowling, CEO of Northwell Health, and Kevin J. Tracey, MD , president and CEO of the Feinstein Institutes, formally unveiled the renovated lab space during a tour with Gov.
  • The Feinstein Institutes, the global scientific home of bioelectronic medicine , is comprised of 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff.

Malaysian Genomics, Rinani Genotec Sign LOI with Universiti Malaysia Sabah

Retrieved on: 
Wednesday, September 21, 2022
Group, National Biotechnology Research Park, Education, Agriculture, Faculty, Dean, Health, Industry, Letter, Genetics, LOI, Natural Resources, Student, Universiti Malaysia Sabah, Goal, B cell, Food security, Genomics, Biosafety, Faculty of Science, Mahidol University, Research, R, University, Cancer, UMS, CAR, Pharmaceutical industry, Management, Science

Parties agree to collaborate on research in genetics, regenerative and alternative medicine

Key Points: 
  • Parties agree to collaborate on research in genetics, regenerative and alternative medicine
    PETALING JAYA, Malaysia, Sept 21, 2022 - (ACN Newswire) - Leading genomics and biopharmaceutical specialist Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155) is pleased to report that the Group has signed a letter of intent (LOI) with the Faculty of Science and Natural Resources, Universiti Malaysia Sabah (UMS) and Rinani Genotec Sdn Bhd (Genotec) to collaborate on research and development (R&D) in genetics, and regenerative and alternative medicines.
  • Chairman of Malaysian Genomics, Datuk Seri Dr. Chen Chaw Min, said, "We are happy to assist UMS undergraduates in pursuing their R&D goals so that they have a better understanding of their field of study.
  • The signing of the LOI followed UMS' visit to MGRC's Biosafety Level 2 cGMP (Current Good Manufacturing Practice)-certified laboratory, which is used for the production of cell therapies, including CAR T-cell therapies for various cancers.
  • Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/
    Copyright 2022 ACN Newswire .

LabShares Newton Doubles Space for Emerging Biotech Startups

Retrieved on: 
Tuesday, July 19, 2022
Health, Commercial Building & Real Estate, Construction & Property, Research, Science, Biotechnology, Newton, Labshare, CEO, Interest, Watertown Square station, Biotechnology, Launch, Biosafety, Thermo Fisher Scientific, I-90, BL2, Founder, Fine chemical, Pharmaceutical industry

In total, LabShares operates over 40,000 square feet of shared lab and office space for over 30 member companies.

Key Points: 
  • In total, LabShares operates over 40,000 square feet of shared lab and office space for over 30 member companies.
  • LabShares is also re-starting the Launch@LabShares Pitch Competition, where one winning startup will be awarded free lab and office space for one year.
  • We are excited to offer free lab space once again to emerging startups as a way of helping them hit the ground running.
  • LabShares Newton is a laboratory incubator for emerging biotechnology and life science start-ups.

Tonix Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Advanced Development Center (ADC) for Vaccine Programs in Massachusetts

Retrieved on: 
Thursday, June 16, 2022
Security (finance), City, Infection, Smallpox, Clinical trial, Monkeypox, Policy, Workforce, Good manufacturing practice, GLOBE, ADC, CNS, Prader–Willi syndrome, CD154, Therapy, Annual report, Technology, Private Securities Litigation Reform Act, Degenerative disease, Hydrogen chloride, SEC, Nasdaq, Biosafety, RDC, FDA, COVID-19, Good, GMP, Government, Medication, Pain, Failure, Neurology, White House, U.S. Securities and Exchange Commission, Cocaine, Psychiatry, Vaccine, SL, Public sector, Company, Technology policy, Cancer, Research, Fibromyalgia, Town, Central nervous system, Long COVID, Autoimmunity, Disease, Risk, Pharmaceutical industry, Tonix Pharmaceuticals

CHATHAM, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it will hold a ribbon-cutting ceremony at the Company’s 45,000 square foot clinical-scale manufacturing facility in the New Bedford Business Park in North Dartmouth, Massachusetts on June 21, 2022 at 1:00 pm ET. The new facility houses Tonix’s Advanced Development Center (ADC) for accelerated research, development and analytical capabilities, as well as the production of clinical trial quality vaccines for infectious diseases, including monkeypox, smallpox and COVID-19 as well as other infectious diseases for pandemic preparedness. The ceremony marks the formal opening of the New Bedford site.

Key Points: 
  • At full capacity, the facility can employ up to 70 researchers, scientists, manufacturing and technical support staff.
  • The addition of Tonix Pharmaceuticals to the growing biotech community in Greater New Bedford is a strong indicator of the quality of the regions workforce.
  • With high quality people, systems and processes, we intend to be a center of excellence for vaccine development.
  • As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products.

Ric Scalzo Institute of Botanical Research and Kelai Pharmaceutical Announce Research Partnership

Retrieved on: 
Tuesday, May 31, 2022
Advanced Drug Delivery Reviews, Knowledge, Canadian College of Naturopathic Medicine, Medicine, Hepatotoxicity, ADD, Botany, Therapy, Nature, Biosafety, Ethanol, Institute, Research, Partnership, SCNM, Intellectual property, Toxicity, Naturopathy, Southwest College of Naturopathic Medicine, Mental health, Outline of health sciences, Brunei Research Department (International), Water, Arizona State University, Pharmaceutical industry

Kava Research Begins at Biosafety Level 2 and Analytical Plant Chemistry Labs

Key Points: 
  • Kelai Pharmaceutical specializes in the development of advanced drug delivery (ADD) technologies that utilize natural compounds to create safer, more effective, and innovative therapies for addiction, mental health disorders, and related conditions
    "We are particularly excited about starting the discovery partnership with the Ric Scalzo Institute for Botanical Research that builds on a rich traditional use of Kava.
  • We see this as the platform for accelerating our forward-looking research and discoveries around Kava," said Jacqueline Jacques, ND, Chief Executive Officer, Kelai Pharmaceutical.
  • When considering botanical material for research, the team analyzes the plant's background, supply chain, ethnobotanical history, and relevant clinical data.
  • For more information on the Ric Scalzo Institute for Botanical Research, visit scnm.edu/research.

SafetyStratus Creates a New Forum for EHS Mindset to Facilitate Safety Community Growth

Retrieved on: 
Monday, May 2, 2022
Knowledge, Comment, Safety management system, Business administration, UF, IBC, Software, Biosafety, Customer success, Occupational Safety and Health Act 1994, Organization, Master of Business Administration, Environmental health officer, Environment, Process, Rest, Learning, EH&S, Mark (given name), EHS, EH, Langston, Goal, Solution, Technology, Motivation, Interview, Awareness, Collection, Construction, Video game, Management, Health care, Health, Biophysical environment, Academy, Safety

PLANO, Texas, May 2, 2022 /PRNewswire-PRWeb/ -- SafetyStratus, the most user-friendly enterprise EH&S software platform company that empowers partners to maximize their Environmental, Health, and Safety (EH&S) programs, announced today that after almost a year of crafting conversations about breakthrough solutions and collaborating with global safety industry professionals, the company has released a dedicated webpage for customers seeking to further their knowledge to access these videos and contribute to the conversation.

Key Points: 
  • The collection of videos known as EHS Mindset began a year ago in April of 2021 with a discussion on Process Improvement with Amy Haberman.
  • These videos have been hosted online but will now be accessible as the third addition to the EH&S Knowledge Network, SafetyStratus Resources.
  • "The motivation behind EHS Mindset was to engage and connect with colleagues in other professions, empowering them to drive safety," says EHS Mindset Host Stephenie Langston.
  • To view the latest EHS Mindset video and comment from your own experience, visit:
    To access the latest from the rest of the EH&S Knowledge Network, visit: https://www.safetystratus.com/resources/
    SafetyStratus is designed by EH&S professionals for EH&S professionals.

Malaysian Genomics Resource Centre Berhad Awarded Covid-19 Surveillance Contract

Retrieved on: 
Monday, April 4, 2022
Asset integrity management systems, CGMP, Ministry of Health (Malaysia), Genomics, Group, CAR, Cell engineering, Certification, Government, Dato, Medical research, IMR, MOH, Biosafety, Knowledge, Coriell Institute for Medical Research, Institute, COVID-19, Ministry, ISO, ISO 9001:2015, Vaccine

PETALING JAYA, Malaysia, Apr 4, 2022 - (ACN Newswire) - Malaysian Genomics Resource Centre Berhad ("Malaysian Genomics" or "the Group"), a leading genomics and biopharmaceutical specialist, was recently awarded a COVID-19 surveillance contract by the Institute for Medical Research ("IMR"), the biomedical research arm of the Ministry of Health ("MOH").

Key Points: 
  • PETALING JAYA, Malaysia, Apr 4, 2022 - (ACN Newswire) - Malaysian Genomics Resource Centre Berhad ("Malaysian Genomics" or "the Group"), a leading genomics and biopharmaceutical specialist, was recently awarded a COVID-19 surveillance contract by the Institute for Medical Research ("IMR"), the biomedical research arm of the Ministry of Health ("MOH").
  • Malaysian Genomics is one of the private laboratories that IMR has engaged to outsource genome surveillance of SARS-CoV2.
  • Dato' Alvin Nesakumar, Executive Director of Malaysian Genomics, said, "We are pleased to support IMR and MOH in this important effort to monitor the evolution of the COVID-19 virus, its variants and sub-variants.
  • Malaysian Genomics Resource Centre Berhad: http://www.mgrc.com.my/
    Copyright 2022 ACN Newswire .

TFF Pharmaceuticals Enters into CRADA with the U.S. Army and The Geneva Foundation to Develop Dry Powder Needle-free Medical Countermeasures

Retrieved on: 
Thursday, March 17, 2022
Department, Research, Technology, Development, Absorption, School of Advanced Warfighting, United States Army Medical Research Institute of Infectious Diseases, Skin, Risk, Biosafety level, United States Army Medical Research and Development Command, Defense, Temperature, RVSV-ZEBOV vaccine, Inhalation, Veteran, Solubility, COVID-19, Government, Infection, Pandemic, Freezing, U.S. Department of Defense Strategy for Operating in Cyberspace, USAMRIID, Biosafety, Program, Health, Therapy, Nose, NASDAQ, Severe acute respiratory syndrome coronavirus 2, TFF, Biological warfare, GLOBE, Annual report, Military, Vaccine, FDA, Institute, Safety, CRADA, Company, Military medicine, Pharmaceutical industry, Virology

Army Medical Researchand Development Command and theU.S Army'spremier institution and facility for defensive research into countermeasures against biological warfare, and The Geneva Foundation, a non-profit that advances innovative medical research within the U.S. military.

Key Points: 
  • Army Medical Researchand Development Command and theU.S Army'spremier institution and facility for defensive research into countermeasures against biological warfare, and The Geneva Foundation, a non-profit that advances innovative medical research within the U.S. military.
  • Current medical countermeasures have become less effective in recent months as new COVID-19 variants have emerged, saidGlenn Mattes, President & Chief Executive Officer ofTFF Pharmaceuticals.
  • TFF Pharmaceuticals continues to engage with various government and defense contracting agencies to utilize its Thin Film Freezing technology platform to formulate dry powder vaccines and therapeutics for mucosal delivery.
  • TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicines into potent dry powder formulations for better efficacy, safety and stability.